Asia competition barometer: pharmaceuticals

Health

Asia competition barometer: pharmaceuticals

Our Editors

The Economist Intelligence Unit

_____________________

Research Methodology

Supported by Singapore’s Economic Development Board (EDB), the Economist Intelligence Unit has developed the Asia Competition Barometer with the aim of understanding the changing market dynamics in key sectors and assessing the intensity of competition in them. Drawing upon company-level data on profitability and other indicators, the Barometer quantifies the changing dynamics of competitiveness in Asia for select industries between 2004 and 2009.

This report focuses on the Barometer findings for the pharmaceutical sector. Assessing a universe of over 350 pharmaceutical companies that are publicly listed in eight countries—China, India, Indonesia, Malaysia, the Philippines, Singapore, Thailand and Vietnam the Barometer examines changing profitability and the competition landscape for the pharmaceutical sector. Other reports in this series look at the information technology services, precision engineering, transport and logistics, and petrochemicals and chemicals sectors in Asia.

Salutation*

First Name*

Last Name*

Job Title*

Company*

Industry*

Country*

Work Email*

Economist Impact is a part of the Economist Group.

Occasionally, we would like to keep you informed about our newly-released content, events, our best subscription offers, and other new product offerings from The Economist Group.

I wish to be contacted by email by the Economist Group:

Hidden blind submit

The Economist Group is a global organisation and operates a strict privacy policy around the world. Please see our privacy policy here.

More from this series

Health

case study

Glenmark Pharmaceuticals: The benefits of longstanding presence

Glenmark Pharmaceuticals, an Indian pharmaceutical company with operations in specialty, generics and out-licensing, has

Health

case study

AstraZeneca: Emphasis on innovation

AstraZeneca, a global biopharmaceutical company, saw Asia Pacific sales rise more than 7% in 2011 to reach US$6bn. Mark

Health

case study

Lonza: Focus on quality

Lonza, a Swiss chemicals and biotechnology firm whose products feed into the pharmaceutical, healthcare and life

Health

Value-based healthcare in Sweden: Reaching the next level

The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.

These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.

This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.

Health

Breast cancer patients and survivors in the Asia-Pacific workforce

With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?

This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.

Health

The Cost of Silence

Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.

As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.

To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.

Download the report to learn more.

Asia competition barometer: pharmaceuticals

Health

Asia competition barometer: pharmaceuticals

Social Share:

Social Share:

Research Methodology

More from this series

Glenmark Pharmaceuticals: The benefits of longstanding presence

AstraZeneca: Emphasis on innovation

Lonza: Focus on quality

Related content

Value-based healthcare in Sweden: Reaching the next level

Breast cancer patients and survivors in the Asia-Pacific workforce

The Cost of Silence